PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing

Abstract Alternative splicing (AS) and the regulation of AS by splicing factors play critical roles in cancer. Plant homeodomain (PHD)–finger domain protein PHF5A, a critical splicing factor involved in AS, has been demonstrated to play an oncogenic role in glioblastoma multiforme and breast cancer,...

Full description

Bibliographic Details
Main Authors: Shuangshuang Mao, Yuan Li, Zhiliang Lu, Yun Che, Jianbing Huang, Yuanyuan Lei, Yalong Wang, Chengming Liu, Xinfeng Wang, Sufei Zheng, Nan Sun, Jie He
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.2115
id doaj-697c203cca1e4252907df9b369ec9643
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Shuangshuang Mao
Yuan Li
Zhiliang Lu
Yun Che
Jianbing Huang
Yuanyuan Lei
Yalong Wang
Chengming Liu
Xinfeng Wang
Sufei Zheng
Nan Sun
Jie He
spellingShingle Shuangshuang Mao
Yuan Li
Zhiliang Lu
Yun Che
Jianbing Huang
Yuanyuan Lei
Yalong Wang
Chengming Liu
Xinfeng Wang
Sufei Zheng
Nan Sun
Jie He
PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
Cancer Medicine
alternative splicing
lung adenocarcinoma
PHF5A
splicing factor
author_facet Shuangshuang Mao
Yuan Li
Zhiliang Lu
Yun Che
Jianbing Huang
Yuanyuan Lei
Yalong Wang
Chengming Liu
Xinfeng Wang
Sufei Zheng
Nan Sun
Jie He
author_sort Shuangshuang Mao
title PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
title_short PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
title_full PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
title_fullStr PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
title_full_unstemmed PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
title_sort phd finger protein 5a promoted lung adenocarcinoma progression via alternative splicing
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2019-05-01
description Abstract Alternative splicing (AS) and the regulation of AS by splicing factors play critical roles in cancer. Plant homeodomain (PHD)–finger domain protein PHF5A, a critical splicing factor involved in AS, has been demonstrated to play an oncogenic role in glioblastoma multiforme and breast cancer, but its biological function in lung cancer remains unclear. In the present study, we systematically analyzed the biological function and clinical relevance of PHF5A in non–small cell lung cancer (NSCLC). We found that PHF5A was significantly upregulated in NSCLC tumors compared with normal tissues in both TCGA data set and tissue microarrays. Upregulation of PHF5A was negatively correlated to the overall survival (OS) of lung adenocarcinoma (LUAD) patients. Loss‐of‐function and gain‐of‐function experiments confirmed that PHF5A functioned as an oncoprotein by promoting LUAD cell proliferation, migration and invasion, inducing G0/G1 cell cycle progression and inhibiting cisplatin–induced apoptosis. RNA–seq analysis identified many essential genes whose AS was dysregulated by PHF5A, including cell cycle–associated genes such as SKP2, CHEK2, ATR and apoptosis–associated genes such as API5 and BCL2L13. Additionally, pladienolide, a small molecular inhibitor of PHF5A, inhibited LUAD cell proliferation in a dose–dependent manner and induced AS changes similar to PHF5A knockdown. In conclusion, we validated that PHF5A played an oncogenic role via AS in LUAD and suggested that PHF5A might serve as a potential drug target with a promising anticancer therapeutic effect.
topic alternative splicing
lung adenocarcinoma
PHF5A
splicing factor
url https://doi.org/10.1002/cam4.2115
work_keys_str_mv AT shuangshuangmao phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT yuanli phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT zhilianglu phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT yunche phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT jianbinghuang phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT yuanyuanlei phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT yalongwang phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT chengmingliu phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT xinfengwang phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT sufeizheng phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT nansun phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
AT jiehe phdfingerprotein5apromotedlungadenocarcinomaprogressionviaalternativesplicing
_version_ 1725979548363784192
spelling doaj-697c203cca1e4252907df9b369ec96432020-11-24T21:26:28ZengWileyCancer Medicine2045-76342019-05-01852429244110.1002/cam4.2115PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicingShuangshuang Mao0Yuan Li1Zhiliang Lu2Yun Che3Jianbing Huang4Yuanyuan Lei5Yalong Wang6Chengming Liu7Xinfeng Wang8Sufei Zheng9Nan Sun10Jie He11Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaAbstract Alternative splicing (AS) and the regulation of AS by splicing factors play critical roles in cancer. Plant homeodomain (PHD)–finger domain protein PHF5A, a critical splicing factor involved in AS, has been demonstrated to play an oncogenic role in glioblastoma multiforme and breast cancer, but its biological function in lung cancer remains unclear. In the present study, we systematically analyzed the biological function and clinical relevance of PHF5A in non–small cell lung cancer (NSCLC). We found that PHF5A was significantly upregulated in NSCLC tumors compared with normal tissues in both TCGA data set and tissue microarrays. Upregulation of PHF5A was negatively correlated to the overall survival (OS) of lung adenocarcinoma (LUAD) patients. Loss‐of‐function and gain‐of‐function experiments confirmed that PHF5A functioned as an oncoprotein by promoting LUAD cell proliferation, migration and invasion, inducing G0/G1 cell cycle progression and inhibiting cisplatin–induced apoptosis. RNA–seq analysis identified many essential genes whose AS was dysregulated by PHF5A, including cell cycle–associated genes such as SKP2, CHEK2, ATR and apoptosis–associated genes such as API5 and BCL2L13. Additionally, pladienolide, a small molecular inhibitor of PHF5A, inhibited LUAD cell proliferation in a dose–dependent manner and induced AS changes similar to PHF5A knockdown. In conclusion, we validated that PHF5A played an oncogenic role via AS in LUAD and suggested that PHF5A might serve as a potential drug target with a promising anticancer therapeutic effect.https://doi.org/10.1002/cam4.2115alternative splicinglung adenocarcinomaPHF5Asplicing factor